TrialsgrambêtaRCTs are beautiful
TCT 2026Présenté dim. 1 nov. · 11:29 UTC−8Late-Breaking Clinical Trials: Session I, in Collaboration with The LancetTous les essais Late-Breaking →

HD-PCI

2026

A Randomized Trial of Higher vs. Lower Dose Heparin for PCI (HD-PCI)

In patients undergoing elective PCI, a higher-dose unfractionated heparin policy did not reduce death, myocardial infarction or target vessel revascularisation at 30 days, or change major bleeding, compared with a lower-dose heparin policy.

Résultat

Efficacité: Death, myocardial infarction or target vessel revascularisation within 30 daysHR 1,29 (IC à 95 % 0,89-1,87)

Sécurité: Major bleedingHR 1,03 (IC à 95 % 0,70-1,52)

En dessous de 1 en faveur de a higher-dose unfractionated heparin policy, au-dessus de 1 en faveur de a lower-dose heparin policy.

Taux d’événements a higher-dose unfractionated heparin policy 1,2% vs a lower-dose heparin policy 1,0% (death, myocardial infarction or target vessel revascularisation within 30 days)

Également rapporté: An activated clotting time was recorded in 39.6% of procedures.

Publication originale
Sous-thème
Periprocedural anticoagulation
Schéma
Cluster-randomised crossover trial of hospital-wide heparin policies for elective PCI (Population Health Research Institute, Canada). Each hospital alternates between a 100 U/kg and a 70 U/kg bolus of unfractionated heparin; outcomes come from linked PCI registries
Inclus
11 619 patients
Source
Jolly S, et al. Presented at TCT 2026, 1 November. Reported by TCTMD (CRF). Not yet published.

Discussion et critique

In a large cluster-crossover trial of elective PCI, a higher-dose heparin policy did not reduce 30-day ischaemic events or change major bleeding, and the source reports that the confidence interval excluded the benefit the trial was powered for. Follow-up was limited to 30 days, event rates were low, and centres rather than patients were randomised, so the trial compares hospital policies rather than individual dosing. The report gives hazard ratios without P values and does not describe blinding, adherence to the assigned policy or a net clinical outcome. These figures come from a news report of the presentation, not a peer-reviewed paper.